European Journal of Cancer · Nov 2026
Beyond Cytotoxic Chemotherapy: Aspirin and Structured Exercise to Reduce Colorectal Cancer Recurrence
By Sabbagh R, Sharma N, Sinicrope FA
Recurrence remains a major cause of morbidity and mortality after curative-intent treatment of stage II–III colorectal cancer (CRC), including among patients receiving adjuvant chemotherapy. Recent randomized trials demonstrate that aspirin and structured exercise can further reduce recurrence risk and improve patient outcomes. Two phase 3 randomized trials provide evidence for extending adjuvant strategies beyond cytotoxic chemotherapy in CRC. In ALASCCA, 3 years of low-dose aspirin reduced recurrence by approximately 50% among patients with resected colon or rectal cancer harboring PI3K-pathway alterations, establishing a biomarker-guided approach to adjuvant aspirin therapy. In CHALLENGE, a 3-year structured exercise program initiated after adjuvant chemotherapy improved disease-free and overall survival in patients with resected stage II or III colon cancer. Mechanistically, aspirin may exert antitumor effects through inhibition of cyclooxygenase and prostaglandin signaling, platelet–tumor interactions, and PI3K-related pathways, whereas exercise may act through metabolic signaling, systemic inflammation, and antitumor immunity. Despite distinct anti-tumor mechanisms, both interventions may converge on inflammation, the tumor microenvironment, and immune surveillance. ALASCCA and CHALLENGE trials provide randomized evidence supporting biomarker-directed aspirin and structured exercise as additional adjuvant strategies in patients with CRC. These study findings support testing for somatic PI3K-pathway alterations to identify patients who may benefit from adjuvant aspirin, and support incorporation of structured exercise into survivorship care after CRC resection. Their distinct mechanisms, and potentially complementary biological effects also provide a rationale for evaluating aspirin and exercise in combination.